首页 | 本学科首页   官方微博 | 高级检索  
     


Double‐blind,randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Authors:Aarti K. Bhatia MD  MPH  Ju‐Whei Lee PhD  Harlan A. Pinto MD  Charlotte D. Jacobs MD  Paul J. Limburg MD  MPH  Robert M. Arusell MD  Eamonn P. Dunphy MD  Janardan D. Khandekar MD  Seth A. Reiner MD  Luis Baez‐Diaz MD  Paul Celano MD  Shuli Li PhD  Yi Li PhD  Barbara A. Burtness MD  Kishan J. Pandya MD
Affiliation:1. Department of Medical Oncology, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut;2. Department of Biostatistics and Computational Biology, Dana‐Farber Cancer Institute, Eastern Cooperative Oncology Group‐ACRIN Biostatistics Center, Boston, Massachusetts;3. Division of Oncology, Department of Medicine, Stanford University and Veterans Affairs Palo Alto Health Care System, Stanford, California;4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;5. Sanford North Fargo Clinic, Fargo, North Dakota;6. Santa Clara Valley Medical Center, San Jose, California;7. North Shore University Health System, Evanston, Illinois;8. Porter Cancer Center, Denver, Colorado;9. San Juan City Hospital, San Juan, Puerto Rico;10. Sandra and Malcolm Berman Cancer Institute, Baltimore, Maryland;11. University of Michigan, Ann Arbor, Michigan;12. Department of Medicine Hematology/Oncology, University of Rochester Medical Center, Rochester, New York
Abstract:
Keywords:chemoprevention  head and neck cancer  oral cancer  randomized controlled trial  second primary cancer
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号